Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2022-04-06 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2021年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and usage of funds raised by the company 康芝药业股份有限公司 for the fiscal year ending December 31, 2021. It references compliance with Chinese regulatory guidelines on the management and use of raised funds, includes detailed tables of fund usage, balances, and investment projects, and contains an auditor's verification report and a sponsor's special inspection report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to the use of raised capital. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual report or audit report, but a specialized report on the use of raised funds as required by regulatory bodies. Therefore, the appropriate classification is CAP.
2022-04-06 Chinese
2021年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2021 年度监事会工作报告' which translates to '2021 Supervisory Board Work Report'. It details the supervisory board's activities during the 2021 fiscal year, including meetings held, approvals of various reports such as the 2020 annual report, quarterly reports, audit reports, and internal control evaluations. The document also contains the supervisory board's opinions on the company's compliance with laws, financial status, use of raised funds, asset transactions, related party transactions, guarantees, internal controls, and insider information management. It concludes with the supervisory board's formal review and approval of the 2021 annual report. The content is a detailed management report on the company's operations and financial oversight for the year, rather than the annual report itself or an announcement of it. The document length is under 5,000 characters but contains substantive supervisory and management commentary on financial and operational matters, consistent with a Management Report (MDA). Therefore, the appropriate classification is Management Reports (MDA).
2022-04-06 Chinese
2021年年度财务报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and investment income confirmation, responsibilities of management and auditors, and extensive notes on accounting policies and financial statement preparation. The document references the fiscal year ending December 31, 2021, and includes detailed financial statement notes and disclosures. The content is consistent with a standalone audit report rather than a full annual report or other filing types. The length of the document (15,000 characters) and the detailed audit content confirm it is not merely an announcement or certification but a full audit report. FY 2021
2022-04-06 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled "康芝药业股份有限公司 2021 年年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2021 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, important matters, shareholder information, and financial statements. The document includes signatures from company officers and auditors, detailed financial metrics for the year 2021, and comprehensive business descriptions. The length is substantial (15,000 characters), and it is not a brief announcement or a certification. The content matches the definition of an Annual Report (10-K) as it covers the full financial performance and company activities for the fiscal year 2021. FY 2021
2022-04-06 Chinese
2022年度投资者关系管理计划
Regulatory Filings Classification · 95% confidence The document is titled '2022 年度投资者关系管理计划' which translates to '2022 Annual Investor Relations Management Plan'. It outlines the company's investor relations management objectives, principles, organizational structure, key work focus, and communication strategies for the year 2022. The content is about the company's plan and approach to managing investor relations rather than a financial report or announcement of financial results. It does not contain financial statements, audit information, or voting results. It is not a report publication announcement since it is a detailed plan document, not a short notice. The document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about investor relations management plan, which does not fall into other specific categories like Annual Report, Earnings Release, or Investor Presentation.
2022-04-06 Chinese
关于股价异动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company 康芝药业股份有限公司. It includes explanations about the stock price movements, confirmations of no undisclosed material information, and risk warnings to investors. It references the upcoming annual report disclosure date but does not contain any financial statements or detailed financial data itself. The document is short (1594 characters) and serves as a regulatory disclosure about stock price movements and company statements rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-04-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.